Circulation

Vol. 153, Issue 4 Issue 4 2026
12
Articles

Articles in this Issue

Recognized Outstanding Reviewers for <i>Circulation</i> in 2025

Victoria Delgado, James A. de Lemos, Joseph A. Hill Jan 27, 2026 pp. 213-213 10.1161/circulationaha.125.079014

Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification

Alexandra Armstrong, Dan Pugh, Neil Basu et al. Jan 27, 2026 pp. 266-281 10.1161/circulationaha.125.076308

Takayasu arteritis (TAK) is a rare, immune-mediated large-vessel vasculitis that affects predominantly young women and carries a substantial risk of both vascular complications and long-term cardiovas...

Letter by He et al Regarding Article, “Targeting uPARAP Modifies Lymphatic Vessel Architecture and Attenuates Lymphedema”

Youfu He, Yu Qian, Yu Zhou Jan 27, 2026 10.1161/circulationaha.125.074622

Anticoagulation and Antiplatelet Therapy Versus Anticoagulation Alone in Patients With Chronic Coronary Syndrome Receiving Long-Term Anticoagulation: A Meta-Analysis of Randomized Clinical Trials

Gilles Lemesle, Romain Didier, Abdourahmane Diallo et al. Jan 27, 2026 pp. 294-296 10.1161/circulationaha.125.077141

Prevalence of Apolipoprotein B and LDL Cholesterol Discordance: Insights From the VLDbL and NHANES

Allison W. Peng, Eugenia Gianos, Michael D. Shapiro et al. Jan 27, 2026 pp. 290-293 10.1161/circulationaha.125.077998

Letter by Ran et al Regarding Article, “Targeting uPARAP Modifies Lymphatic Vessel Architecture and Attenuates Lymphedema”

Qingzhi Ran, Yongkang Zhang, Hengwen Chen Jan 27, 2026 10.1161/circulationaha.125.074549

An Atypical Presentation of an Occlusion Myocardial Infarction Requiring Urgent Revascularization

Qinghua Chang, Changjun Li, Zhaolong Xu Jan 27, 2026 pp. 282-284 10.1161/circulationaha.125.078556

Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Marianna Fontana, Pablo Garcia-Pavia, Martha Grogan et al. Jan 27, 2026 pp. 214-225 10.1161/circulationaha.125.077304

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive disease caused by the deposition of transthyretin (TTR) as amyloid in the myocardium. Current therapies m...

Rapidly Progressive Pulmonary Hypertension: Importance of Vascular Disease Distribution

Atsushi Tada, Ahmed U. Fayyaz, Yogesh N.V. Reddy et al. Jan 27, 2026 pp. 285-289 10.1161/circulationaha.125.078277

Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome

Sergio Leonardi, Antonio Landi, Andrea Zito et al. Jan 27, 2026 pp. 230-242 10.1161/circulationaha.125.077174

BACKGROUND: The universal definition of percutaneous coronary intervention (PCI)–related myocardial infarction (MI) has been substantially updated over the years, including an incr...

miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction

Lee Ohayon-Steckel, Xinyi Zhang, Shagufta Haque et al. Jan 27, 2026 pp. 243-259 10.1161/circulationaha.124.073527

BACKGROUND: Emergency myelopoiesis by bone marrow hematopoietic stem and progenitor cells (HSPCs) exacerbates disease pathology in various chronic diseases, including myocardial in...

Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy?

Michel G. Khouri, Jan M. Griffin Jan 27, 2026 pp. 226-229 10.1161/circulationaha.125.078276

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0009-7322
E-ISSN 1524-4539
Subject Health Sciences
Language English
View Full Journal Page